Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSanidad

5.72 -4.19

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

5.53

Máximo

6.04

Métricas clave
By Trading Economics
Ingresos	-34M -43M
Ventas	-37M 8.3M
BPA	-0.14
Margen de beneficios	-519.122
Empleados	562
EBITDA	-23M -41M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+70.85% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	169M 1.8B
Apertura anterior	9.91
Cierre anterior	5.72

Noticias sobre sentimiento de mercado

By Acuity

50%

145 / 340 Clasificación en Healthcare

AbCellera Biologics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 jul 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc previsión

Precio Objetivo

By TipRanks

70.85% repunte

Estimación a 12 Meses

Media 10.2 USD 70.85%

Máximo 13 USD

Mínimo 7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.